FY2025 · ended Dec 31, 2025 · Revenue $4.86M, -3.7% YoY · Filed Mar 26, 2026
Arcadia Biosciences, Inc. (RKDA) files with the SEC under industry code 1311, Crude Petroleum & Natural Gas. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $4.9 million and a net loss of $2.3 million. Free cash flow was -$4.7 million.
Revenue (TTM)
$4.75M
-12.2% vs year-ago TTM
Net income (TTM)
$-11.13M
-47.7% vs year-ago TTM
Operating cash flow (TTM)
$-2.50M
+67.1% vs year-ago TTM
Free cash flow
$-4.74M
+50.9% vs prior year
EPS (TTM)
$-5.71
-3.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.06M
+0.0% vs prior year
Net cash
$4.56M
FY 2025
Operating margin
-80.2%
FY 2026
Company profile
- Industry
- Crude Petroleum & Natural Gas (SIC 1311)
- Listed as
- RKDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1469443
Other Crude Petroleum & Natural Gas companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.9M | $5.0M | $4.5M | $7.4M | $6.8M |
| Operating income | -$2.5M | -$3.6M | -$6.1M | -$14.0M | -$35.5M |
| Net income | -$2.3M | -$7.0M | -$14.0M | -$15.4M | -$14.7M |
| Diluted EPS | -$1.71 | -$5.17 | — | -$25.65 | — |
| Operating cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$25.9M |
| Free cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$26.9M |
| Total assets | $6.5M | $13.5M | $19.7M | $28.9M | $43.9M |
| Total liabilities | $2.4M | $7.3M | $7.0M | $8.0M | $12.7M |
| Stockholders' equity | $4.1M | $6.2M | $12.7M | $20.9M | $31.2M |
| Cash and investments | $4.6M | $4.2M | $11.6M | $20.6M | $28.7M |
| Total debt | $0 | $155,000 | $1.0M | $2.0M | $3.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 15, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 4, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| ARS | Annual report to shareholders | Aug 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Listing notice
|
Aug 10, 2026 | Aug 4, 2026 |
All 596 Arcadia Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.